Fate Therapeutics Stock Today
| FATE Stock | USD 5.27 0.11 2.04% |
Performance5 of 100
| Odds Of DistressLess than 42
|
Fate Therapeutics is trading at 5.27 as of the 18th of April 2024, a -2.04 percent decrease since the beginning of the trading day. The stock's lowest day price was 5.21. Fate Therapeutics has about a 42 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Fate Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of March 2024 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of October 2013 | Category Healthcare | Classification Health Care |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. The company has 113.78 M outstanding shares of which 16.49 M shares are currently shorted by private and institutional investors with about 5.95 trading days to cover. More on Fate Therapeutics
Moving together with Fate Stock
| 0.88 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.76 | JSPRW | Jasper Therapeutics | PairCorr |
Moving against Fate Stock
| 0.47 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 1st of May 2024
Fate Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Fate Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Fate Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Scott Wolchko | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Fate Therapeutics report their recommendations after researching Fate Therapeutics' financial statements, talking to executives and customers, or listening in on Fate Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Fate Therapeutics. The Fate consensus assessment is calculated by taking the average forecast from all of the analysts covering Fate Therapeutics. | |||||
Fate Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Fate Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Fate Therapeutics' financial leverage. It provides some insight into what part of Fate Therapeutics' total assets is financed by creditors.
| |||||
Fate Therapeutics (FATE) is traded on NASDAQ Exchange in USA. It is located in 12278 Scripps Summit Drive, San Diego, CA, United States, 92131 and employs 181 people. Fate Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 642.87 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fate Therapeutics's market, we take the total number of its shares issued and multiply it by Fate Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Fate Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 113.78 M outstanding shares of which 16.49 M shares are currently shorted by private and institutional investors with about 5.95 trading days to cover.
Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Fate Therapeutics Probability Of Bankruptcy
Ownership AllocationFate Therapeutics holds a total of 113.78 Million outstanding shares. The majority of Fate Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Fate Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Fate Therapeutics. Please pay attention to any change in the institutional holdings of Fate Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Fate Ownership Details
Fate Stock Price Odds Analysis
What are Fate Therapeutics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Fate Therapeutics jumping above the current price in 90 days from now is about 87.54%. The Fate Therapeutics probability density function shows the probability of Fate Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 4.1241. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Fate Therapeutics will likely underperform. Additionally, fate Therapeutics has an alpha of 0.2019, implying that it can generate a 0.2 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Fate Therapeutics to move above the current price in 90 days from now is about 87.54 (This Fate Therapeutics probability density function shows the probability of Fate Stock to fall within a particular range of prices over 90 days) .
Fate Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Fate Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fate Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fate Therapeutics' value.| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2023-09-30 | 2 M | |
| Two Sigma Advisers, Llc | 2023-12-31 | 1.9 M | |
| Geode Capital Management, Llc | 2023-12-31 | 1.9 M | |
| State Street Corporation | 2023-12-31 | 1.9 M | |
| Federated Hermes Inc | 2023-12-31 | 1.8 M | |
| Adage Capital Partners Gp Llc | 2023-12-31 | 1.7 M | |
| Two Sigma Investments Llc | 2023-12-31 | 1.6 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.3 M | |
| Vestal Point Capital Lp | 2023-12-31 | 1.3 M | |
| Redmile Group, Llc | 2023-09-30 | 13.1 M | |
| Blackrock Inc | 2023-12-31 | 11.2 M |
Fate Therapeutics Historical Income Statement
Fate Therapeutics Income Statement is one of the three primary financial statements used for reporting Fate's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Fate Therapeutics revenue and expense. Fate Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Fate Therapeutics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 85.5 M, whereas Operating Income is projected to grow to (168.7 M). View More FundamentalsFate Stock Against Markets
Picking the right benchmark for Fate Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Fate Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Fate Therapeutics is critical whether you are bullish or bearish towards Fate Therapeutics at a given time. Please also check how Fate Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Fate Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Fate Therapeutics Corporate Directors
Fate Therapeutics corporate directors refer to members of a Fate Therapeutics board of directors. The board of directors generally takes responsibility for the Fate Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Fate Therapeutics' board members must vote for the resolution. The Fate Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Robert Epstein | Director | Profile | |
| Michael Lee | Director | Profile | |
| Shefali Agarwal | Director | Profile | |
| Timothy Coughlin | Independent Director | Profile |
How to buy Fate Stock?
Before investing in Fate Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Fate Therapeutics. To buy Fate Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Fate Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Fate Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Fate Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Fate Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Fate Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Fate Stock please use our How to Invest in Fate Therapeutics guide.
Already Invested in Fate Therapeutics?
The danger of trading Fate Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Fate Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Fate Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Fate Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.646 | Quarterly Revenue Growth (0.96) | Return On Assets (0.18) | Return On Equity (0.38) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.